Unexpected Cross-neutralization of Cutaneous & Mucosal Papillomavirus Types with Anti-Sera to a Novel L2 Epitopes

Case ID:

C04603

C04603: Unexpected Cross-neutralization of Cutaneous & Mucosal Papillomavirus Types with Anti-Sera to a Novel Epitopes
Technical Details:
High risk Human Papillomavirus (HPV) infection is a common cause of cervical cancer. Researchers at JHU have found that vaccination with the N terminus of HPV16 and bovine papillomavirus 1 can induce cross neutralizing antibodies that inhibit in vitro generated pseudovirus infection of both cutaneous and genital types that infect both humans and animals.
Looking for Partners:
The invention could be developed into a simple protein-based vaccine to broadly prevent genital and cutaneous papillomavirus infections. The fact that the vaccination appears to have such a wide spectrum of activity against animal papillomavirus suggests that it could be developed for veterinarian use as well.

Patent Information:

Title	App Type	Country	Serial No.	Patent No.	File Date	Issued Date	Expire Date	Patent Status
Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies	PCT: Patent Cooperation Treaty	Australia	2006210792	2006210792	2/1/2006	11/8/2012	2/1/2026	Granted
Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies	PCT: Patent Cooperation Treaty	European Patent Office	06734177.6	1853307	2/1/2006	12/14/2016	2/1/2026	Granted
Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies	PCT: Patent Cooperation Treaty	China	200680011079.1	ZL 200680011079.1	2/1/2006	3/27/2013	2/1/2026	Granted
Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies	PCT: Patent Cooperation Treaty	Canada	2,596,698	2,596,698	2/1/2006	5/16/2017	2/1/2026	Granted
Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies	PCT: Patent Cooperation Treaty	Japan	2007-554194	5224821	2/1/2006	3/22/2013	2/1/2026	Granted
Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies	PCT: Patent Cooperation Treaty	Brazil	PI0607097-3	PI 0607097-3	2/1/2006	9/24/2020	2/1/2026	Granted
Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies	PCT: Patent Cooperation Treaty	India	6219/DELNP/2007	263255	2/1/2006	10/16/2014	2/1/2026	Granted
Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies	PCT: Patent Cooperation Treaty	France	06734177.6	1853307	2/1/2006	12/14/2016	2/1/2026	Granted
Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies	PCT: Patent Cooperation Treaty	United Kingdom	06734177.6	1853307	2/1/2006	12/14/2016	2/1/2026	Granted
Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies	PCT: Patent Cooperation Treaty	Germany	06734177.6	1853307	2/1/2006	12/14/2016	2/1/2026	Granted
Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies	PCT: Patent Cooperation Treaty	United States	11/883,495	8,404,244	5/13/2008	3/26/2013	3/23/2028	Granted
Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies	CON: Continuation	United States	13/772,893	9,388,221	2/21/2013	7/12/2016	2/1/2026	Granted

Direct Link:

https://jhu.technologypublisher.com/technology/16367

Inventors:

Category(s):

Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Cervical Cancer, Clinical and Disease Specializations > Women's Health, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Human Papillomavirus (HPV),

Get custom alerts for techs in these categories/from these inventors:

Subscribe for JHTV Updates

For Information, Contact:

Vera Sampels

vsampel2@jhu.edu

410-614-0300

Save This Technology:

Bookmark this page

Download as PDF